文献速递胸部肿瘤

阿美替尼用于EGFR突变NSCLC术后辅助治疗的ARTS三期试验

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-01-12

ARTS研究是一项双盲、多中心、随机对照三期试验,纳入中国48家医院II-IIIB期EGFR突变NSCLC完全切除后患者,1:1随机接受阿美替尼110mg或安慰剂口服3年。

要点

  • 最常见3-4级不良事件为血肌酸磷酸激酶升高(7% vs 0)。

核心结论

  • 阿美替尼在中国II-IIIB期EGFR突变NSCLC完全切除后患者中作为辅助治疗显示出显著临床获益。
  • 阿美替尼的安全性可控,支持其用于辅助治疗场景。

研究设计与样本

  • 双盲、多中心、随机、对照、三期试验,在中国大陆48家医院入组。
  • 214例患者随机1:1接受阿美替尼110 mg或安慰剂口服,每日一次,持续3年或直至疾病复发。
  • 主要终点为BICR评估的mITT人群无病生存期。

主要发现

  • 阿美替尼组最常见3-4级不良事件为血肌酸磷酸激酶升高(7% vs 0)、心电图QT间期延长(3% vs 3%)、高血压(1% vs 5%)和肺炎(2% vs 3%)。
  • 治疗相关严重不良事件在阿美替尼组为1%(1例),安慰剂组为3%(3例)。
  • 未发生治疗相关死亡,未发现阿美替尼新的安全性信号。

临床怎么用

  • 对于II-IIIB期EGFR ex19del或Leu858Arg突变的NSCLC患者,完全切除及标准辅助治疗后可考虑阿美替尼辅助治疗。
  • 治疗期间需监测血肌酸磷酸激酶、心电图QT间期、血压和肺炎等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with resectable non-small-cell lung cancer (NSCLC), particularly those with EGFR mutations, face a high risk of recurrence and mortality post-surgery. Aumolertinib, a third-generation EGFR tyrosine-kinase inhibitor, is approved in China for adjuvant treatment in patients with NSCLC harbouring EGFR with an exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation. The ARTS study aimed to evaluate the efficacy and safety of adjuvant therapy with aumolertinib in patients with stage II-IIIB EGFR-mutated NSCLC. METHODS: This double-blind, multicentre, randomised, controlled, phase 3 trial enrolled patients from 48 hospitals in mainland China. Eligible patients were 18 years or older with stage II-IIIB NSCLC, had undergone a complete resection followed by standard adjuvant therapy, and had an EGFR ex19del or Leu858Arg mutation and an Eastern Cooperative Oncology Group performance status score of 0 or 1. Patients were stratified by EGFR mutation status and tumour stage and were randomly assigned (1:1) to receive aumolertinib 110 mg or placebo orally, once daily for 3 years or until disease recurrence or other discontinuation criteria were met. Patients were randomly allocated to groups using an interactive web response system; the double‑dummy technique masked patients, investigators, and assessors. The primary endpoint was disease-free survival in the modified intention-to treat (mITT) population (ie, all patients with stage II-IIIB NSCLC harbouring EGFR mutations who had undergone complete tumour resection and standard adjuvant therapy), assessed by blinded independent central review (BICR). Safety was assessed in all patients who received at least one dose of study treatment. Although the study is ongoing, with some patients remaining in follow-up, this analysis represents the protocol-specified primary analysis. This study is registered with ClinicalTrials.gov (NCT04687241). FINDINGS: Between April 30, 2021, and May 17, 2022, 399 individuals were screened for study eligibility; of these, 214 patients were randomly assigned to receive aumolertinib or placebo (107 in each group). 120 (56%) patients were female, 94 (44%) were male, median age was 59 years (IQR 54-66), and all patients were Chinese. 204 (95%) of 214 patients had received prior adjuvant chemotherapy. One patient in the aumolertinib group and three patients in the placebo group had stage I disease; therefore, 106 patients in the aumolertinib group and 104 in the placebo group were included in the mITT (primary analysis) population. As of the data cutoff date (April 15, 2024), the median duration of follow-up was 27·56 months (IQR 22·18-27·70) in the aumolertinib group and 27·63 months (22·18-27·79) in the placebo group. The BICR-assessed disease-free survival was significantly improved in the aumolertinib group compared with the placebo group, with an HR of 0·17 (95% CI 0·09-0·29, p<0·0001). The median disease-free survival per BICR in the aumolertinib group was not reached (95% CI 29·14 to not applicable), whereas it was 19·42 months (11·24-26·22) in the placebo group. The most common grade 3-4 adverse events in the aumolertinib group versus the placebo group were increased blood creatine phosphokinase (seven [7%] vs none), prolonged electrocardiogram QT interval (three [3%] vs three [3%]), hypertension (one [1%] vs five [5%]), and pneumonia (two [2%] vs three [3%]). Treatment-related serious adverse events occurred in one (1%) patient receiving aumolertinib and three (3%) patients receiving placebo. No treatment-related deaths occurred and no new safety signals were identified for aumolertinib. INTERPRETATION: Aumolertinib showed substantial clinical benefits as adjuvant therapy in Chinese patients with stage II-IIIB EGFR-mutated NSCLC. The manageable safety profile of aumolertinib supports its suitability in the adjuvant setting. FUNDING: Hansoh Pharmaceutical Group. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Zhang X, Wu L, et al. Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 41539318. doi:10.1016/S1470-2045(25)00643-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。